← All trials
NCT06265688
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 2, 2024
- Primary completion
- Nov 30, 2027
- Completion date
- Mar 31, 2029
- First posted
- Feb 20, 2024
- Last posted
- Jun 7, 2024
- Enrollment
- 124
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CytomX TherapeuticsLead sponsor
- CytomX TherapeuticsOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.